AK117 + Placebo + Azacitidine
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Higher-risk Myelodysplastic Syndromes
Conditions
Higher-risk Myelodysplastic Syndromes
Trial Timeline
Feb 7, 2024 → Jun 1, 2026
NCT ID
NCT06196203About AK117 + Placebo + Azacitidine
AK117 + Placebo + Azacitidine is a phase 2 stage product being developed by Akeso for Higher-risk Myelodysplastic Syndromes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06196203. Target conditions include Higher-risk Myelodysplastic Syndromes.
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06196203 | Phase 2 | Recruiting |